ADAPY · Adaptimmune Therapeutics PLC · Debt
$0.03
-0.01 (-18.92%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$31.81M
Shares
1.59B
Volume · Oct 5
234.5K
Avg daily vol (3M)
243.49K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent debt carrying amount | 2025-06-30 | USD 25,675,000 | 10-Q filed 2025-08-13 |
| Operating lease liabilities | 2025-06-30 | USD 23,005,000 | 10-Q filed 2025-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.